Biogen Inc


Want a discount? Become a member by purchasing Annual Subscription!
SKU: BIIB-1 Category:


Biogen delivered a strong result and managed an all-around beat last quarter. The last quarter saw decreased total revenue, but the company delivered a solid performance overall. The decline in Multiple Sclerosis (MS) product revenues was due to generic entrants for TECFIDERA and intense competition in the MS market. However, they saw positive growth in SPINRAZA and Biosimilars revenue. Despite headwinds from Alzheimer’s disease revenue and other factors, the company is progressing with cost-saving initiatives and the new Fit for Growth program. Biogen reaffirmed its full-year guidance for 2023, expecting a mid-single-digit percentage decline in revenue compared to the previous year and non-GAAP diluted earnings per share of between $15 and $16. The company remains focused on driving growth and innovation to achieve its financial goals. Implementing cost-saving measures and the new Fit for Growth program is expected to further strengthen Biogen’s financial position. Biogen also recently announced 1,000 job cuts to prioritize new drug launches. We give Biogen Inc a ‘Hold’ rating with a revised target price.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!